Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Prospectively study of neuropsychiatric (NP) events in1827 SLE - found that NP-SLE occured in 52%; with 31% directly attributed to SLE. Risk of NP-SLE was highest in the first 2 years (RR 6.16) and mortality risk was higher in NP-SLE pts ((16% vs 7%) https://t.co/03wfX5SxNm
Dr. John Cush RheumNow
Study of 260 TB patients treated with pyrazinamide or fluoroquinolones showed a higher risk of joint pain (mostly ankles knees) with FQN (29%) vs PZA (17%); median latency was 55 days vs 138 days; half had hyperuricemia. https://t.co/ylc4Az0yOz
Dr. John Cush RheumNow
ENTRACTE trial studied the risk of major adverse CV events (MACE) in 3080 RA pts Rx with tocilizumab (TCZ) vs etanercept (ETN), and found no increased risk of MACE in TCZ patients compared to ETN (HR 1.05 (95% condence interval 0.77–1.43). https://t.co/QxOlzfDcZD

